Biogen Idec Inc $290.54

down -0.94


17/4/2014 08:10 PM  |  NASDAQ : BIIB  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BIIB Trend Analysis - it has outperformed the S&P 500 by 22%

Partner Headlines

  1. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  2. Stocks: Thin Gains; Yellen Coaxes Banks To Fortify

    IBD
  3. Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual ...

    Benzinga
  4. IPO Frenzy Freezes As 4 New Issues Delayed

    IBD
  5. Stocks Hit Again; Nasdaq Ends Below 4000

    IBD
  6. Hemophilia drug draws plaudits

    IBD
  7. Market Wrap For April 10: Wednesday's Rally Completely Forgotten

    Benzinga
  8. Biotech IPOs Adamas, Cerulean Slump In Trading Debut

    IBD
  9. Software, Biotech, Solar Names Weigh on Nasdaq

    IBD
  10. Sellers Dictate Action As Growth Stocks Tumble Again

    IBD
  11. Stocks Fall Hard In Early Trade; Biotechs Take Heat Again

    IBD
  12. Stocks Mixed, Volume Mixed; HP, IBM, AT&T Rise

    IBD
  13. Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours

    IBD
  14. Stocks Extend Gains; Trimble Navigation Finds Support

    IBD
  15. Alexion, Biogen Among Leading Big-Cap Biotechs

    IBD
  16. Don't Panic Over Recent Tech Turmoil

    FoxBusiness
  17. Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump

    IBD
  18. Biotechs Struggling To Find A Bottom

    Benzinga
  19. Biogen Idec May Have Seeds For Next-Gen MS Drugs

    IBD
  20. Stocks Weaken In Late Trade; Questcor Pares Gains

    IBD
  21. Major Averages Face More Selling, Biotechs Rally Back

    IBD
  22. IBD 50 Stocks Fade With Market; Some Trip Sell Rules

    IBD
  23. Stocks Fall Ahead Of Jobs Data; Palo Alto, Tableau Slide

    IBD
  24. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  25. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  26. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  27. Trial Results Lift Drug Sector

    IBD
  28. Stocks Hold Gains After Yellen Comments; Biotechs Bounce

    IBD
  29. Gilead Adds To Biotech Woes

    IBD
  30. Gains Fade Into Quiet Finish

    IBD
  31. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  32. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  33. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  34. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  35. Biotech ETFs Come Back Down To Earth

    Benzinga
  36. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  37. Baxter To Split Into Two Companies; Stock Jumps

    IBD
  38. BIOGEN IDEC

    IBD
  39. Top Industry Groups Take Big Hits In Market Sell-Off

    IBD
  40. Nasdaq Pierces 50-Day Line; Growth Stocks Fall Hard Again

    IBD
  41. Have We Seen The Top Of The Market?

    Benzinga
  42. Nasdaq Under Heavy Fire As Leaders Crumble

    IBD
  43. Dems Question Gilead Price

    IBD
  44. Biotechs, Medicals Get Hurt Amid Price-Inquiry News

    IBD
  45. Biotechs, Software, Generics Pace U.S. Stocks Lower

    IBD
  46. House Probe Of Gilead's Sovaldi Price Hits Biotechs

    IBD
  47. U.S. Stocks Lose Gains, Biotechs Get Hammered

    IBD
  48. Use Pyramiding Into A Full Position To Reduce Risk

    IBD
  49. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  50. Pharmacyclics target raised

    IBD
Trading Center